Acrivon Therapeutics (ACRV) Competitors $8.01 +0.01 (+0.13%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ACRV vs. MESO, PHAT, APLT, CRGX, PAHC, ZYME, CGEM, SANA, PRTA, and CRONShould you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Mesoblast (MESO), Phathom Pharmaceuticals (PHAT), Applied Therapeutics (APLT), CARGO Therapeutics (CRGX), Phibro Animal Health (PAHC), Zymeworks (ZYME), Cullinan Therapeutics (CGEM), Sana Biotechnology (SANA), Prothena (PRTA), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry. Acrivon Therapeutics vs. Mesoblast Phathom Pharmaceuticals Applied Therapeutics CARGO Therapeutics Phibro Animal Health Zymeworks Cullinan Therapeutics Sana Biotechnology Prothena Cronos Group Mesoblast (NASDAQ:MESO) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability. Which has more risk & volatility, MESO or ACRV? Mesoblast has a beta of 3.47, indicating that its share price is 247% more volatile than the S&P 500. Comparatively, Acrivon Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Do analysts rate MESO or ACRV? Mesoblast currently has a consensus price target of $11.50, indicating a potential upside of 35.61%. Acrivon Therapeutics has a consensus price target of $23.83, indicating a potential upside of 197.54%. Given Acrivon Therapeutics' higher probable upside, analysts clearly believe Acrivon Therapeutics is more favorable than Mesoblast.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Acrivon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, MESO or ACRV? Acrivon Therapeutics has lower revenue, but higher earnings than Mesoblast. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMesoblast$5.90M164.05-$87.96MN/AN/AAcrivon TherapeuticsN/AN/A-$60.39M-$2.77-2.89 Do insiders and institutionals have more ownership in MESO or ACRV? 1.4% of Mesoblast shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 8.5% of Acrivon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer MESO or ACRV? Mesoblast received 378 more outperform votes than Acrivon Therapeutics when rated by MarketBeat users. However, 96.88% of users gave Acrivon Therapeutics an outperform vote while only 70.27% of users gave Mesoblast an outperform vote. CompanyUnderperformOutperformMesoblastOutperform Votes40970.27% Underperform Votes17329.73% Acrivon TherapeuticsOutperform Votes3196.88% Underperform Votes13.13% Does the media prefer MESO or ACRV? In the previous week, Mesoblast and Mesoblast both had 4 articles in the media. Acrivon Therapeutics' average media sentiment score of 0.96 beat Mesoblast's score of 0.40 indicating that Acrivon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acrivon Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is MESO or ACRV more profitable? Mesoblast's return on equity of 0.00% beat Acrivon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MesoblastN/A N/A N/A Acrivon Therapeutics N/A -47.31%-43.10% SummaryMesoblast and Acrivon Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Ad Chaikin AnalyticsSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRV vs. The Competition Export to ExcelMetricAcrivon TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$248.07M$7.02B$5.39B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-2.899.47113.8115.12Price / SalesN/A381.571,483.2593.03Price / CashN/A47.3339.6434.05Price / Book1.495.324.665.02Net Income-$60.39M$153.56M$119.06M$225.46M7 Day Performance0.63%0.12%0.79%0.37%1 Month Performance12.66%15.23%5.65%3.57%1 Year Performance48.88%41.16%36.76%29.42% Acrivon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRVAcrivon Therapeutics3.4126 of 5 stars$8.01+0.1%$23.83+197.5%+57.7%$248.07MN/A-2.8958Short Interest ↓Positive NewsMESOMesoblast2.3933 of 5 stars$8.58-1.0%$11.50+34.0%+256.3%$979.66M$5.90M0.0080News CoveragePHATPhathom Pharmaceuticals1.154 of 5 stars$16.70+4.0%$22.50+34.7%+90.1%$977.53M$9.92M-3.26110Upcoming EarningsNews CoverageAPLTApplied Therapeutics4.2104 of 5 stars$8.50+0.8%$12.50+47.1%+291.8%$971.27M$-333,000.00-5.3130CRGXCARGO Therapeutics1.5447 of 5 stars$20.95+1.7%$30.33+44.8%N/A$960.81MN/A-0.41116Short Interest ↑PAHCPhibro Animal Health4.214 of 5 stars$23.60+0.7%$15.00-36.4%+107.1%$955.87M$1.02B393.401,940Upcoming EarningsZYMEZymeworks1.9399 of 5 stars$13.34+3.2%$15.25+14.3%+89.2%$947.81M$76.01M-8.78290Earnings ReportAnalyst DowngradeNews CoverageGap DownCGEMCullinan Therapeutics2.1469 of 5 stars$16.23+1.7%$31.67+95.1%+70.0%$935.40M$18.94M-5.3030Analyst RevisionNews CoverageSANASana Biotechnology2.6444 of 5 stars$3.93+4.5%$14.25+262.6%+18.4%$874.31MN/A-3.42328Gap UpPRTAProthena3.2104 of 5 stars$16.23+6.1%$61.86+281.1%-54.6%$872.72M$217.25M-16.23173Upcoming EarningsCRONCronos Group1.3232 of 5 stars$2.25+1.4%$3.00+33.3%+24.1%$860.13M$101.78M-15.00356 Related Companies and Tools Related Companies Mesoblast Competitors Phathom Pharmaceuticals Competitors Applied Therapeutics Competitors CARGO Therapeutics Competitors Phibro Animal Health Competitors Zymeworks Competitors Cullinan Therapeutics Competitors Sana Biotechnology Competitors Prothena Competitors Cronos Group Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACRV) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
